Brief: Medicinova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of Mn-166 (Ibudilast)
05/12/2024 23:07
Dec 5 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA PRESENTS STUDY UPDATE AND INTERIM ANALYSIS OF
PHASE
2/3 CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS (COMBAT-ALS
CLINICAL TRIAL) AT THE 35TH INTERNATIONAL SYMPOSIUM ON ALS/MND
* MEDICINOVA INC - POSITIVE CORRELATIONS OBSERVED BETWEEN
6-MONTH
AND 12-MONTH DATA
* MEDICINOVA INC - EXPECTS TO COMPLETE PATIENT ASSIGNMENTS
BY JUNE
2025 WITH TRIAL RESULTS EXPECTED IN 2026
Source text: ID:nGNX72vMw4
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake